Elsevier

Vaccine

Volume 28, Issue 18, 19 April 2010, Pages 3086-3094
Vaccine

Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy

https://doi.org/10.1016/j.vaccine.2010.02.065Get rights and content

Abstract

Fijian infants aged 6 weeks were stratified by ethnicity and randomized to receive 0, 1, 2, or 3 PCV-7 doses with or without the 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months. Strong booster effects for all 7 PCV-7 serotypes were elicited, and for 4/7 serotypes these responses were highest in the single PCV-7 group. There were fourfold rises in GMC for all non-PCV-7 serotypes. By 17 months the PPV-23 group still had significantly higher GMC (each p < 0.001) for all serotypes. The PPV-23 was well tolerated and induced excellent responses for all serotypes which were greatest in the single PCV-7 group.

Introduction

Streptococcus pneumoniae is the most common cause of bacterial pneumonia in children worldwide. It is the leading vaccine preventable cause of serious infection in infants [1]. A recent review estimated that over 14 million episodes of serious pneumococcal disease occurred worldwide in the year 2000, with over 800,000 deaths in children under 5 years [2]. The case fatality rate is particularly high in infants less than 6 months old [3]. At least 48 serogroups comprising over 90 serotypes of pneumococcus have been identified [4]. Within serogroups, some serotypes cross-react immunologically, and in some cases this translates into cross-protection such as antibodies against 6B which provide cross-protection against 6A [5]. The association of particular serotypes with disease varies according to age, geography, and clinical presentation [6]. In general, the range of serotypes causing invasive pneumococcal disease (IPD) in affluent countries like the United States and in Europe is relatively narrow and largely confined to the serotypes found in the 7-valent pneumococcal conjugate vaccine (PCV-7, Prevenar™, Wyeth Vaccines). In contrast, the range of serotypes causing disease in low-income countries is wider.

The 10-valent pneumococcal conjugate vaccine has recently been licensed in some countries, and a 13-valent vaccine is likely to be licensed by 2010. Some health authorities have decided or are considering a combination of an infant PCV-7 primary series with a booster of the 23-valent pneumococcal polysaccharide vaccine (PPV-23) in the second year of life to address the limited serotype coverage offered by PCV-7. There have been several studies involving children in a number of countries using different pneumococcal conjugate formulations and schedules, comparing the immunogenicity of a PPV-23 or PCV-7 booster following a pneumococcal conjugate vaccine primary series. The majority of studies have shown that serotype-specific antibody concentrations are generally higher following PPV-23 than PCV-7 booster [7], [8], [9], [10], [11], [12]. The higher response may be due to the higher dose of pneumococcal polysaccharide in the PPV-23, compared to PCV-7, enhancing the stimulation of memory B cells or by stimulating a greater number of B cells overall [13]. Despite this, only pneumococcal conjugate vaccines provide mucosal immunity and have shown a reduction in nasopharyngeal (NP) carriage (NP carriage being an antecedent event for all pneumococcal disease) for conjugate serotypes, compared with unvaccinated infants [14], [15], [16] or toddlers [17], [18], [19]. In contrast, pneumococcal polysaccharide vaccines have shown no effect on pneumococcal carriage [20], [21], [22], [23], [24]. Most studies evaluating the impact of pneumococcal polysaccharide immunization in the absence of additional PCV-7 in infants or children have not shown any impact on pneumococcal disease or carriage [25], [26], [27]

Data from Fiji shows that the 7 serotypes included in PCV-7, plus the cross reactive serotype 6A, would potentially cover 63.3% of invasive pneumococcal disease (IPD) cases in children under 5 years [28]. This coverage would potentially increase to 83% if the PPV-23 was used, and would increase to 87% if the new 13-valent pneumococcal conjugate vaccine produced by Wyeth Vaccines (which includes serotypes 1, 3, 5, 6A, 7F and 19A) was used, largely due to the inclusion of 6A which is not included in the PPV-23 [28]. The aim of this study was to find an optimal vaccination strategy suitable for resource poor countries in terms of serotype coverage, flexibility, and affordability. To address these issues, we undertook a Phase II vaccine trial in Fiji to document the safety, immunogenicity and impact on pneumococcal carriage of various pneumococcal vaccination regimens combining 1, 2, or 3 doses of PCV-7 in infancy. In order to broaden the serotype coverage, the additional benefit of a PPV-23 booster at 12 months of age was also assessed. Presented are the geometric mean serotype-specific IgG antibody concentrations (GMC) prior to and 2 weeks following the 12 month PPV-23, and at 17 months of age.

Section snippets

Study participants

The study was a single blind, open-label randomized Phase II vaccine trial undertaken in Suva, the capital of Fiji. Healthy infants aged between six and eight weeks were eligible for enrolment. Details of the selection criteria and the randomization procedure have been reported elsewhere [29]

The study was conducted and monitored according to Good Clinical Practice. It was approved by the Fiji National Research Ethics Review Committee and the University of Melbourne Human Research Ethics

Results

There were 552 infants enrolled in the study (Fig. 1) and the characteristics of the randomized infants have been described elsewhere (15). The 552 participants represent a consent rate of 30.5%, of which 10% had withdrawn by 12 months and 15% by 17 months of age. The commonest reason for withdrawal was relocation outside the study area. No participant was withdrawn due to a reaction to any of the vaccines. The 12-month PPV-23 was administered to 245 children with all groups having blood drawn

Discussion

This study has shown that 1, 2, or 3 doses of PCV-7 in infancy primed infants sufficiently elicit an excellent booster response to the PPV-23 at 12 months of age for all PCV-7 serotypes. Furthermore, there were good antibody responses to the 16 non-PCV-7 serotypes following PPV-23 at 12 months. The antibody concentrations for all 23 serotypes remained significantly higher at 17 months of age in the PPV-23 group compared to the group that had not received PPV-23.

In addition, this study has shown

Acknowledgments

The authors wish to sincerely thank all the FiPP staff and families participating in the study, the Fiji Ministry of Health, CWMH laboratory and paediatric department, and the many other people who contributed to the study including: Amanda O’Brien, Kathryn Bright, Amy Bin Chen, Timothy Gemetzis, Amy Auge, Katherine Gilbert, Evan Willis, Philip Greenwood, Beth Temple, Vanessa Johnston, Loretta Thorn, Porter Anderson, Brian Greenwood, George Siber, David Klein, Elizabeth Horigan, Farukh

References (48)

  • F.M. Russell et al.

    Vaccine

    (2010)
  • Conclusions from the WHO multicenter study of serious infections in young infants. The WHO Young Infants Study Group....
  • F.W. Denny et al.

    Acute respiratory infections are the leading cause of death in children in developing countries

    Am J Trop Med Hyg

    (1986)
  • I.H. Park et al.

    Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae

    J Clin Microbiol

    (2007)
  • C.G. Whitney et al.

    Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine

    N Engl J Med

    (2003)
  • GAVI's PneumoADIP, Department of International Health, Health. JHBSoP. Pneumococcal Regional Serotype Distribution for...
  • H. Ahman et al.

    Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory

    Pediatr Infect Dis J

    (1998)
  • S. Choo et al.

    Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a haemophilus influenzae type B conjugate vaccine in United Kingdom infants

    Pediatr Infect Dis J

    (2000)
  • D. Goldblatt et al.

    Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers

    Pediatr Infect Dis J

    (2006)
  • T. Kilpi et al.

    Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children

    Clin Infect Dis

    (2003)
  • N. Mbelle et al.

    Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine

    J Infect Dis

    (1999)
  • R. Lakshman et al.

    Pneumococcal nasopharyngeal carriage in children following heptavalent pneumococcal conjugate vaccination in infancy

    Arch Dis Child

    (2003)
  • R. Dagan et al.

    Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine

    J Infect Dis

    (1996)
  • R.H. Veenhoven et al.

    Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media

    Clin Infect Dis

    (2004)
  • Cited by (0)

    View full text